Atomoxetine, a diminutive molecule drug concocted by Eli Lilly, procured its inaugural medical approval in 2002.

FDA Approves NMD Pharma's IND Application for Phase 2b Trial of NMD670 in US Myasthenia Gravis Population.

On March 18th, Bristol Myers Squibb (BMS) finalized its acquisition of Karuna Therapeutics, enhancing its neuroscience investments. Karuna has stopped NASDAQ trading and is now fully owned by BMS.

Molecure S.A. is dedicated to finding new treatments for diseases once thought incurable, focusing on small-molecule and mRNA-based drugs. The company is now conducting a Phase II trial of their drug OATD-01 for active pulmonary sarcoidosis.

Midodrine, a diminutive molecule of therapeutic nature, exhibits its therapeutic effect through its agonistic action upon the α-adrenergic receptor.

Mission Therapeutics has initiated a pivotal study on MTX325, which could potentially alter the progression of Parkinson’s Disease.

Sumitomo Dainippon Pharma and its U.S. subsidiary SMPA announced an updated agreement on March 15th with Otsuka Pharmaceutical for the joint development of four psychiatric and neurological compounds, including ulotaront and others, amending their original September 30, 2021, partnership.

FDA Clears Italfarmaco's Duvyzat™ (givinostat) for Treatment of Duchenne Muscular Dystrophy.

Indomethacin is a small NSAID that blocks the COX enzyme to reduce inflammation and pain.

Vertex has received authorization from the FDA to proceed with clinical trials for VX-407, a new drug candidate targeting the management of ADPKD.

On March 14, AstraZeneca plans to buy Amolyt Pharma, a biotech firm specializing in rare endocrine disorders, enhancing its Alexion unit with the phase III drug, eneboparatide, for hypoparathyroidism treatment.

Sosei Heptares reclaims complete control over HTL0027477 from GSK, a pioneering oral GPR35 activator set for clinical trials in treating inflammatory bowel conditions.